Cargando…

Identification of GPD1L as a Potential Prognosis Biomarker and Associated with Immune Infiltrates in Lung Adenocarcinoma

Lung adenocarcinoma (LUAD) is one of the most prevalent pathological kinds of lung cancer, which is a common form of cancer that has a high death rate. Over the past several years, growing studies have indicated that GPD1L was involved in the advancement of a number of different cancers. However, it...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Zhengyang, Wu, Song, Sang, Hongyang, Li, Qianping, Cheng, Shaofei, Zhu, Hongling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079383/
https://www.ncbi.nlm.nih.gov/pubmed/37035759
http://dx.doi.org/10.1155/2023/9162249
_version_ 1785020717312507904
author Fan, Zhengyang
Wu, Song
Sang, Hongyang
Li, Qianping
Cheng, Shaofei
Zhu, Hongling
author_facet Fan, Zhengyang
Wu, Song
Sang, Hongyang
Li, Qianping
Cheng, Shaofei
Zhu, Hongling
author_sort Fan, Zhengyang
collection PubMed
description Lung adenocarcinoma (LUAD) is one of the most prevalent pathological kinds of lung cancer, which is a common form of cancer that has a high death rate. Over the past several years, growing studies have indicated that GPD1L was involved in the advancement of a number of different cancers. However, its clinical significance in LUAD has not been investigated. In this study, following an examination of the TGCA datasets, we found that GPD1L displayed a dysregulated state in a wide variety of cancers; this led us to believe that GPD1L is an essential regulator in the progression of malignancies. In addition, we found that the expression of GPD1L was much lower in LUAD tissues when compared with nontumor specimens. According to the findings of ROC tests, GPD1L was able to effectively identify LUAD specimens from nontumor samples with an AUC value of 0.828 (95% confidence interval: 0.793 to 0.863). On the basis of the clinical study, a low expression of GPD1L was clearly related with both the N stage and the clinical stage. Moreover, based on the findings of a Kaplan-Meier survival study, elevated GPD1L expression was a strong indicator of considerably improved overall survival (OS) and disease-specific survival (DSS). GPD1L expression and clinical stages were found to be independent prognostic indicators for overall survival and disease-free survival in LUAD patients, according to multivariate analyses. Based on multivariate analysis, the C-indexes and calibration plots of the nomogram demonstrated an effective prediction performance for LUAD patients. Besides, the expression of GPD1L was positively related to mast cells, eosinophils, Tcm, TFH, iDC, DC, and macrophages, while negatively associated with Th2 cells, NK CD56dim cells, Tgd, Treg, and neutrophils. Finally, qRT-PCR was able to demonstrate that GPD1L had a significant amount of expression in LUAD. Additionally, according to the results of functional tests, overexpression of GPD1L had a significant inhibiting effect on the proliferation of LUAD cells. In general, the results of our study suggested that GPD1L had the potential to serve as a diagnostic and prognostic marker for LUAD.
format Online
Article
Text
id pubmed-10079383
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-100793832023-04-07 Identification of GPD1L as a Potential Prognosis Biomarker and Associated with Immune Infiltrates in Lung Adenocarcinoma Fan, Zhengyang Wu, Song Sang, Hongyang Li, Qianping Cheng, Shaofei Zhu, Hongling Mediators Inflamm Research Article Lung adenocarcinoma (LUAD) is one of the most prevalent pathological kinds of lung cancer, which is a common form of cancer that has a high death rate. Over the past several years, growing studies have indicated that GPD1L was involved in the advancement of a number of different cancers. However, its clinical significance in LUAD has not been investigated. In this study, following an examination of the TGCA datasets, we found that GPD1L displayed a dysregulated state in a wide variety of cancers; this led us to believe that GPD1L is an essential regulator in the progression of malignancies. In addition, we found that the expression of GPD1L was much lower in LUAD tissues when compared with nontumor specimens. According to the findings of ROC tests, GPD1L was able to effectively identify LUAD specimens from nontumor samples with an AUC value of 0.828 (95% confidence interval: 0.793 to 0.863). On the basis of the clinical study, a low expression of GPD1L was clearly related with both the N stage and the clinical stage. Moreover, based on the findings of a Kaplan-Meier survival study, elevated GPD1L expression was a strong indicator of considerably improved overall survival (OS) and disease-specific survival (DSS). GPD1L expression and clinical stages were found to be independent prognostic indicators for overall survival and disease-free survival in LUAD patients, according to multivariate analyses. Based on multivariate analysis, the C-indexes and calibration plots of the nomogram demonstrated an effective prediction performance for LUAD patients. Besides, the expression of GPD1L was positively related to mast cells, eosinophils, Tcm, TFH, iDC, DC, and macrophages, while negatively associated with Th2 cells, NK CD56dim cells, Tgd, Treg, and neutrophils. Finally, qRT-PCR was able to demonstrate that GPD1L had a significant amount of expression in LUAD. Additionally, according to the results of functional tests, overexpression of GPD1L had a significant inhibiting effect on the proliferation of LUAD cells. In general, the results of our study suggested that GPD1L had the potential to serve as a diagnostic and prognostic marker for LUAD. Hindawi 2023-03-30 /pmc/articles/PMC10079383/ /pubmed/37035759 http://dx.doi.org/10.1155/2023/9162249 Text en Copyright © 2023 Zhengyang Fan et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Fan, Zhengyang
Wu, Song
Sang, Hongyang
Li, Qianping
Cheng, Shaofei
Zhu, Hongling
Identification of GPD1L as a Potential Prognosis Biomarker and Associated with Immune Infiltrates in Lung Adenocarcinoma
title Identification of GPD1L as a Potential Prognosis Biomarker and Associated with Immune Infiltrates in Lung Adenocarcinoma
title_full Identification of GPD1L as a Potential Prognosis Biomarker and Associated with Immune Infiltrates in Lung Adenocarcinoma
title_fullStr Identification of GPD1L as a Potential Prognosis Biomarker and Associated with Immune Infiltrates in Lung Adenocarcinoma
title_full_unstemmed Identification of GPD1L as a Potential Prognosis Biomarker and Associated with Immune Infiltrates in Lung Adenocarcinoma
title_short Identification of GPD1L as a Potential Prognosis Biomarker and Associated with Immune Infiltrates in Lung Adenocarcinoma
title_sort identification of gpd1l as a potential prognosis biomarker and associated with immune infiltrates in lung adenocarcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079383/
https://www.ncbi.nlm.nih.gov/pubmed/37035759
http://dx.doi.org/10.1155/2023/9162249
work_keys_str_mv AT fanzhengyang identificationofgpd1lasapotentialprognosisbiomarkerandassociatedwithimmuneinfiltratesinlungadenocarcinoma
AT wusong identificationofgpd1lasapotentialprognosisbiomarkerandassociatedwithimmuneinfiltratesinlungadenocarcinoma
AT sanghongyang identificationofgpd1lasapotentialprognosisbiomarkerandassociatedwithimmuneinfiltratesinlungadenocarcinoma
AT liqianping identificationofgpd1lasapotentialprognosisbiomarkerandassociatedwithimmuneinfiltratesinlungadenocarcinoma
AT chengshaofei identificationofgpd1lasapotentialprognosisbiomarkerandassociatedwithimmuneinfiltratesinlungadenocarcinoma
AT zhuhongling identificationofgpd1lasapotentialprognosisbiomarkerandassociatedwithimmuneinfiltratesinlungadenocarcinoma